Clostridium difficile Infection and Fecal Microbiota Transplant
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Clostridium difficile infection (CDI) is a major source of morbidity and mortality for hospitalized patients. Although most patients have a clinical response to existing antimicrobial therapies, recurrent infection develops in up to 30% of patients. Fecal microbiota transplant is a novel approach to this complex problem, with an efficacy rate of nearly 90% in the setting of multiple recurrent CDI. This review covers the current epidemiology of CDI (including toxigenic and nontoxigenic strains, risk factors for infection, and recurrent infection), methods of diagnosis, existing first-line therapies in CDI, the role of fecal microbiota transplant for multiple recurrent CDIs, and the potential use of fecal microbial transplant for patients with severe or refractory infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708 · cited 1×
“In the single randomized control trial for FMT, recurrent CDI was resolved in 81% of patients compared with 31% who received nontapered/nonpulsed vancomycin.(83) FMT performed via lower routes of administration (colonoscopy or enema) appear to be more successful than upper routes (gastroscopy, or nasogastric and nasoi…”
BackgroundBurden of Clostridium difficile Infection in the United States
Lessa, F. C., Mu, Y., Bamberg, W. M., Beldavs, Z. G., Dumyati, G. K., Dunn, J. R., Farley, M. M., Holzbauer, S. M., Meek, J. I., Phipps, E. C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1408913 · Cited by 2,641 · cited 2×
“3 cases per 100 000 population.(15) In the community, the rate of first recurrence was 13.”
BackgroundDethlefsen, L., Huse, S., Sogin, M. L., & Relman, D. A. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060280 · Cited by 2,361 · cited 1×
“Subsequent alterations in bile acids, sugar alcohols, and fatty acids can promote growth of C difficile.(79,80) The bulk of evidence for FMT exists for multiple recurrent CDI.”
BackgroundGuidelines for diagnosis, treatment, and prevention of Clostridium difficile infections
Surawicz, C. M., Brandt, L. J., Binion, D. G., Ananthakrishnan, A. N., Curry, S. R., Gilligan, P. H., McFarland, L. V., Mellow, M., & Zuckerbraun, B. S. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.4 · Cited by 1,645
Treating Clostridium difficile infection with fecal microbiota transplantation
Bakken, J. S., Borody, T., Brandt, L. J., Brill, J. V., Demarco, D. C., Franzos, M. A., Kelly, C., Khoruts, A., Louie, T., Martinelli, L. P., et al. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.08.014 · Cited by 1,003
Theriot, C. M., Koenigsknecht, M. J., Carlson, P. E., Hatton, G. E., Nelson, A. M., Li, B., Huffnagle, G. B., Z. Li, J., & Young, V. B. (2014) · Nature Communications · doi:10.1038/ncomms4114 · Cited by 974
Khoruts, A., Dicksved, J., Jansson, J. K., & Sadowsky, M. J. (2010) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181c87e02 · Cited by 649 · cited 1×
“Patients with recurrent CDI are deficient in the bacterial phyla that normally dominate the colon, which may predispose them to multiple recurrences.(30) Risk Factors for C difficile”
BackgroundKelly, C. R., Ihunnah, C., Fischer, M., Khoruts, A., Surawicz, C., Afzali, A., Aroniadis, O., Barto, A., Borody, T., Giovanelli, A., et al. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.133 · Cited by 636
Youngster, I., Russell, G. H., Pindar, C., Ziv-Baran, T., Sauk, J., & Hohmann, E. L. (2014) · JAMA · doi:10.1001/jama.2014.13875 · Cited by 629
Should we standardize the 1,700-year-old fecal microbiota transplantation?
Zhang, F., Luo, W., Shi, Y., Fan, Z., & Ji, G. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.251 · Cited by 619 · cited 2×
“It was again documented as “yellow soup” in 16th-century China by Li Shizhen for the treatment of gastrointestinal diseases in his book, Bencao Gangmu.(73) A similar practice to FMT, called “rumen transfaunation,” is widely used in veterinary medicine and was first documented in Sweden in 1776.”
BackgroundHickson, M., D'Souza, A. L., Muthu, N., Rogers, T. R., Want, S., Rajkumar, C., & Bulpitt, C. J. (2007) · BMJ · doi:10.1136/bmj.39231.599815.55 · Cited by 599 · cited 1×
“Saccharomyces boulardii and Lactobacillus have been reported to decrease the incidence of antibioticassociated diarrhea in a recent meta-analysis and several previous studies.(65,66) Although researchers in initial reports found that Saccharomyces boulardii decreased CDI recurrence when used as adjunctive therapy with…”
ResultUpdate on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook
Kelly, C. R., Kahn, S., Kashyap, P., Laine, L., Rubin, D., Atreja, A., Moore, T., & Wu, G. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.008 · Cited by 572 · cited 2×
“The current guidelines on FMT recommend using a donor questionnaire similar to those used with blood donation followed by serologic and stool assessment for infectious risk (Table 3) and exclusion of other conditions that could potentially be related to transmission of disease (Table 4).(78,89) Much of the exclusion c…”
BackgroundMethodCammarota, G., Ianiro, G., & Gasbarrini, A. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000046 · Cited by 428
Hamilton, M. J., Weingarden, A. R., Unno, T., Khoruts, A., & Sadowsky, M. J. (2013) · Gut Microbes · doi:10.4161/gmic.23571 · Cited by 315 · cited 5×
“Frozen stool maintains its molecular integrity and is effective in FMT.90 FMT via oral capsule with frozen feces has a efficacy rate similar to that of FMT via fresh stool.81 Nasointestinal (nasogastric or nasojejunal) tube FMT requires placement of the tube, which involves risk of vomiting (and aspiration) as well as…”
BackgroundInfluentialShahinas, D., Silverman, M., Sittler, T., Chiu, C., Kim, P., Allen-Vercoe, E., Weese, S., Wong, A., Low, D. E., & Pillai, D. R. (2012) · mBio · doi:10.1128/mbio.00338-12 · Cited by 191
Neemann, K., Eichele, D. D., Smith, P. W., Bociek, R., Akhtari, M., & Freifeld, A. (2012) · Transplant Infectious Disease · doi:10.1111/tid.12017 · Cited by 107
Weingarden, A. R., Hamilton, M. J., Sadowsky, M. J., & Khoruts, A. (2013) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31829004ae · Cited by 87
Dorsey, K. A., Moritz, E. D., Steele, W. R., Eder, A. F., & Stramer, S. L. (2013) · Transfusion · doi:10.1111/j.1537-2995.2012.03904.x · Cited by 40
Cited by
The promise of the gut microbiome as part of individualized treatment strategies
Schupack, D. A., Mars, R. A. T., Voelker, D. H., Abeykoon, J. P., & Kashyap, P. C. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00499-1 · Cited by 217
Lorente-Picón, M., & Laguna, A. (2021) · Biomolecules · doi:10.3390/biom11030433 · Cited by 69
Wei, J., Liu, C., Qin, D., Ren, F., Duan, J., Chen, T., & Wu, A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102544 · Cited by 15
Metadata
- Authors
- Liubakka, A., & Vaughn, B. P.
- Venue
- AACN Advanced Critical Care
- Publisher
- AACN Publishing
- Published
- 2016-07-01
- Volume
- 27
- Issue
- 3
- Pages
- 324-337
- ISSN
- 1559-7768 (ISSN-L)
- 1559-7776
- OpenAlex
- W2498097469
- Cited by
- 71
- References
- 18
- FWCI
- 2.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.